3-{4-[(2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl)sulfonyl]phenyl}propanoic acid, and a pharmaceutically acceptable salt thereof is disclosed. Also disclosed is the use of said compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating inflammation or pain caused or potentiated by prostaglandins, leukotrienes, or platelet activation factor in a mammal. This compound is particularly suitable for treating asthma, rheumatoid arthritis, osteoarthritis, juvenile arthritis, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, and central nervous system damage resulting from trauma.
Inhibitors of cytosolic phospholipase A2